CSIMarket Company Name, Ticker, Suppliers, else..
 
Alumis inc   (NASDAQ: ALMS)
 
Price: $9.4700 $-12.34 -56.580%
Day's High: $11.055999755859375 Week Perf: -59.91 %
Day's Low: $ 8.76 30 Day Perf: -63.74 %
Volume (M): 28,230,215 52 Wk High: $ 31.35
Volume (M$): $ 0 52 Wk Avg: $18.48
Open: $9.93 52 Wk Low: $3.76



 Market Capitalization (Millions $) 1,184
 Shares Outstanding (Millions) 125
 Employees 224
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -237
 Cash Flow (TTM) (Millions $) -64
 Capital Exp. (TTM) (Millions $) 1

Business Description


Alumis Inc. is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. Its lead programs include two TYK2 inhibitors: envudeucitinib (envu), for treating plaque psoriasis and systemic lupus erythematosus, and A-005, a CNS-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company also acquired lonigutamab, a monoclonal antibody for potential treatment of Thyroid Eye Disease, through a merger with ACELYRIN, Inc.


   Company Address: 280 East Grand Avenue South San Francisco 94080 CA
   Company Phone Number: 231-6625   Stock Exchange / Ticker: NASDAQ ALMS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Merger and Acquisition

Alumis Inc. Ends 2024 Strong with Solid Financial Wins and Strategic Merger to Transform Immunology Treatments,

Published Wed, Mar 19 2025 8:05 PM UTC

A Year of Growth and TransformationAlumis Inc. (NASDAQ: ALMS), a prominent player in the pharmaceutical industry, specifically in Major Pharmaceutical Preparations, recently released its year-end financial results for 2024, alongside significant corporate milestones. The firm s share price comfortably rests at $4.70, reflecting a stable market position bolstered by strategi...
Merger and Acquisition

Alumis and ACELYRIN Unite to Propel Innovation in Immune-mediated Disease Therapies: Merger Announcement Reaffirms Strategic and Financial Growth Prospects

Published Tue, Mar 4 2025 2:01 PM UTC

Breaking News Date: February 6, 2025 In a groundbreaking announcement today, Alumis and ACELYRIN have officially reaffirmed their commitment to a proposed merger that promises to reshape the landscape of biopharmaceutical innovation, particularly in the treatment of immune-mediated diseases. This strategic alliance aims to leverage the strengths of both companies, combining...
Merger and Acquisition

Biopharma Revolution: Alumis and ACELYRIN Join Forces to Lead Innovation in Transformative Therapies for Immune-mediated Diseases,

Published Thu, Feb 6 2025 9:15 PM UTC

Alumis and ACELYRIN to Merge: Paving the Way for Transformative Therapies Against Immune-mediated DiseasesIntroductionIn a significant development in the biopharmaceutical sector, Alumis and ACELYRIN have announced plans to merge, creating a formidable late-stage clinical company focused on developing and commercializing transformative therapies for immune-mediated diseases...
Clinical Study

Advancing Neuroscience Promising Phase 1 Results of TYK2 Inhibitor A-005 in CNS Disorders

Published Thu, Dec 19 2024 1:00 PM UTC

The therapeutic landscape for central nervous system (CNS) disorders is evolving, with advancements in targeted biologics leading to new avenues for treatment. A recent announcement by Alumis regarding the positive results from a Phase 1 trial of the oral TYK2 inhibitor A-005 highlights a significant step forward in this field. This article reviews the findings from the tri...
Clinical Study

Advancements in Systemic Lupus Erythematosus Treatment Unveiling the Efficacy of ESK-001, a Novel Oral TYK2 Inhibitor

Published Thu, Nov 14 2024 9:05 PM UTC

: Systemic Lupus Erythematosus (SLE) poses a considerable challenge in rheumatology due to its heterogeneous nature and the varied response to treatments. Recent data presented at ACR Convergence 2024 by Alumis highlights ESK-001, a novel oral TYK2 inhibitor, demonstrating high-efficacy potential in the management of SLE. This article discusses the implications of these fin...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 140.95
Price to Sales (Expected) -
Price to Book 2.09
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.9
Working Capital Ratio 7.51
Leverage Ratio (MRQ) 0.18
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.12 $
Revenues (TTM) 0.07 $
Cash Flow (TTM) -
Cash 0.51 $
Book Value 4.53 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 37,509
Net Income per Employee (TTM) -1,059,888
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -5652.44 %
Net Margin (MRQ) -5344.8 %
Net Cash Flow Margin (MRQ) -1480.76 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Alumis Inc's Segments
Collaboration    100 % of total Revenue
Single reportable segment    100 % of total Revenue
Single reportable Collaboration    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.